A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

NCT02642432 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus Infection
Chronic Hepatitis C
Compensated Cirrhosis

Interventions

DRUG: ABT-493/ABT-530

Sponsor

AbbVie